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Abstract
Background: Buruli Ulcer is a tropical skin disease caused by Mycobacterium ulcerans, which, due to scarring and
contractures can lead to stigma and functional limitations. However, recent advances in treatment, combined with
increased public health efforts have the potential to significantly improve disease outcome.
Objectives: To study the Quality of Life (QoL) of former Buruli Ulcer patients who, in the context of a randomized controlled
trial, reported early with small lesions (cross-sectional diameter ,10 cm), and received a full course of antibiotic treatment.
Methods: 127 Participants of the BURULICO drug trial in Ghana were revisited. All former patients aged 16 or older
completed the Dermatology Life Quality Index (DLQI) and the abbreviated World Health Organization Quality of Life scale
(WHOQOL-BREF). The WHOQOL-BREF was also administered to 82 matched healthy controls. Those younger than 16
completed the Childrens’ Dermatology Life Quality Index (CDLQI) only.
Results: The median (Inter Quartile Range) score on the DLQI was 0 (0–4), indicating good QoL. 85% of former patients
indicated no effect, or only a small effect of the disease on their current life. Former patients also indicated good QoL on the
physical and psychological domains of the WHOQOL-BREF, and scored significantly higher than healthy controls on these
domains. There was a weak correlation between the DLQI and scar size (r= 0.32; p,0.001).
Conclusions: BU patients who report early with small lesions and receive 8 weeks of antimicrobial therapy have a good QoL
at long-term follow-up. These findings contrast with the debilitating sequelae often reported in BU, and highlight the
importance of early case detection.
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Introduction
Buruli ulcer (BU) is listed by the World Health Organization
(WHO) as a neglected tropical disease, caused by infection with
Mycobacterium ulcerans. Although the disease has been reported from
as many as 30 countries around the world, it is currently most
common in West and Central Africa, and it predominantly affects
the rural poor. Typically, the disease starts with a small, painless
nodule that progresses into a large necrotizing ulcer over the
course of several weeks. After treatment, although the ulcer usually
heals, there is a high risk of significant scarring, contractures and
functional limitations [1–3].
In the socio-economic context of rural Africa, functional
limitations and stigmatizing scars can have severe consequences.
In a study of 638 former BU patients in Ghana and Benin, 57%
appeared to have a functional limitation, and school dropout,
financial difficulties and job loss were frequent consequences of the
disease [2]. People in endemic communities sometimes perceive
the disease to be caused by a curse or witchcraft, and the resulting
stigma can cause social isolation and problems with finding work
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or a spouse [4–6]. Although the treatment for BU is free of charge,
the costs associated with hospitalization can be devastating for the
household economy and frequently cause family members to cease
providing financial and social support to patients [7].
However, over the past decade, the main mode of treatment has
shifted from surgery to antibiotics, with high rates of cure [8]. In
addition, significant public health efforts have been directed at
detecting BU at an early stage and educating affected communities
about the disease. Conceptually, both factors combined should
reduce scarring, contractures, and stigma, and improve the
subsequent quality of life (QoL) of former patients.
To our knowledge, the QoL of former BU patients has not yet
been studied. In leprosy and podoconiosis, similarly deforming and
stigmatizing skin conditions occurring in the tropics, several studies
on QoL have been conducted in Bangladesh, Brazil, China,
Ethiopia, Ghana, and India [9–15]. In general, these studies show
that patients report a substantially lower QoL than controls [9–
11]. There appears to be some relationship between QoL and the
severity of the disease in terms of number of lesions, functional
limitations, stigma, and deformities [11–15]. Studies from Ethiopia
in podoconiosis patients, a disabling and stigmatizing geochemical
elephantiasis of the foot, found that a dermatology-specific QoL
instrument was valid and sensitive to therapeutic change [16,17].
These studies demonstrate that measuring QoL with standard-
ized questionnaires in rural Africans suffering from skin diseases is
feasible. Moreover, as both leprosy and podoconiosis were shown
to have a significant impact on QoL they show that measuring
QoL in these populations is warranted. In the current study, we
report on the disease-specific and general QoL of former BU
patients who previously presented with small, early ulcers and who
were treated with a full course of 8 weeks of antibiotics.
Methods
Sample size and patient recruitment
Our study subjects were former BU patients that had earlier
participated in the BURULICO trial, conducted between 2006
and 2009 in Ghana, registered with number NCT00321178 at
clinicaltrials.gov. For that trial, patients aged 5 years or older,
clinically diagnosed with early (duration ,6 months), limited
(cross-sectional diameter of induration ,10 cm, including plaques
and oedemas) M. ulcerans infection were included, and randomized
to receive either 8 weeks of streptomycin at 15 mg/kg daily (max
1000 mg daily) and rifampicin at 10 mg/kg daily (max 600 mg
daily), or 4 weeks of streptomycin and rifampicin, followed by 4
weeks of rifampicin and clarithromycin at 7.5 mg/kg daily. The
rate of healing did not differ between both arms. Patients had a
median age of 12 and 30% were male [8].
For the present follow-up study, participants were traced
between June and November 2012 by visiting their last known
village or through telephone contact if available. If the former
patient was no longer living at the last known village, neighbors,
relatives, and community leaders were asked for additional
information. When a former patient was located, he or she was
informed about the study, given time to consider participation,
and asked for consent.
Questionnaires
The Cardiff Dermatologic Life Quality Index (DLQI) and its
pediatric adaptation the Childrens Dermatologic Life Quality
Index (CDLQI) are dermatology-specific QoL instruments
[18,19]. Both contain 10 questions with scores on a question
ranging from 0 to 3. The total score is calculated by summing the
score of each question resulting in a maximum of 30 and a
minimum of 0. The higher the score, the more QoL is impaired.
In addition, to facilitate interpretation, banding scores are
available for both the DLQI and CDLQI, with a score of 0 or
1 indicating no effect, a score between 2 and 5 a small effect, a
score between 6 and 10 a moderate effect, a score between 11
and 20 a very large effect, and a score between 21 and 30 an
extremely large effect on the patients’ life. The DLQI was
designed for patients aged 16 or above, and the CDLQI for those
aged between 4 and 16. Both the DLQI and CDLQI have been
extensively validated, but only the DLQI has been used in low
and middle Income countries, including sub-Sahara Africa
[9,16,20,21]. Both the DLQI and CDLQI were translated into
the local language, Twii, according to the instructions of the
authors of the original questionnaires. Two independent trans-
lators separately translated the questionnaire from English into
Twii, and discussed their translations to arrive at a single Twii
translation. A third and fourth translator then independently
translated the questionnaires back into English. Next, the back-
translations were reviewed by the original authors of the
questionnaire. After initial comments and a subsequent cycle of
translation and back-translation, the questionnaire authors
approved this back-translation for further use. Finally the agreed
translation was pretested in a group of 8 former BU patients that
did not participate in the BURULICO trial, asking them about
the clarity, understandability and wording of the questions. In
this pretest no further issues arose.
The WHO Quality of Life-BREF (WHOQOL-BREF), is an
international cross-culturally comparable generic QoL assess-
ment instrument [22]. It assesses the individuals’ perceptions in
the context of their culture and value systems, and their personal
goals, standards and concerns. It comprises 26 items, which
measure 4 domains: physical health, psychological health, social
relationships, and environment (satisfaction with one’s living
conditions). In addition, two questions measure general health
and general QoL. The score on each question ranges between 1
and 5, and for each domain a total score is computed that
ranges between 20 and 100, with a higher score indicating a
better QoL. No specific age range is given for the WHOQOL-
BREF, but it was designed for adults. The WHOQOL-BREF
was also translated into Twii according to the procedure
outlined above for the DLQI and CDLQI, with the exception
Author Summary
Buruli ulcer is an infectious skin disease, mainly occurring
in West Africa. It usually starts with a small nodule that
over the course of weeks progresses into an ulcer. Effective
treatment with antibiotics is available, but patients often
report to the hospital late, and there is a serious risk of
scarring, contractures and functional limitations of the
affected body parts. Although it is often reported that
Buruli ulcers can have serious sequelae, the quality of life
of former Buruli ulcer patients has not been studied
before. In this study we assessed the quality of life of
healed Buruli ulcer patients that took part in a drug trial
between 2006 and 2009, which only included small and
early lesions. On follow-up, we found that most scars were
small and functional limitations were rare, and that both
general and skin specific Quality of Life was good. Our
results demonstrate the potential of the combination of
early detection and proper antibiotic treatment of Buruli
ulcer and hence stress the importance of public health
efforts aimed at diagnosing the disease in its early stage,
and providing standardized treatment in endemic areas.
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that the back translations were not reviewed by the authors of
the questionnaire but by the study team. Effect sizes of the
difference in WHOQOL-BREF domains between former
patients and controls were calculated using the formula z/!N,
where z is the z-score of the U statistic, and N is the total sample
size.
The Buruli Ulcer Functional Limitation Score (BUFLS) is a
questionnaire that consists of questions related to 19 common daily
activities of people living in endemic areas [2,23]. Each item is
scored between 0 and 2, with 0 indicating no difficulties in
performing the activity compared to age- and sex matched
community members, 1 indicating difficulties performing the
activity, and 2 indicating that the former patient is unable to carry
out the activity at all. In the calculation of the individual functional
limitation score, the sum is divided by the maximum possible score
for that individual, multiplied by 100%. A higher score therefore
indicates more functional limitations, with a range between 0%
and 100%. A score cannot be calculated if more than 6 items are
not applicable.
Procedures
Former patients currently aged 16 or above were administered
the WHOQOL-BREF, DLQI and BUFLS questionnaires, and
former patients currently aged below 16 were administered the
CDLQI and BUFLS only. The WHOQOL-BREF was also
administered to 82 age, sex, and occupation (farming, schooling
or other) matched healthy controls that lived in the same villages
as the former BU patients on separate visits. All potential controls
were asked whether they were currently sick or injured, and
whether they were on any medication; they could only
participate if they answered both questions with no. Due to
high rates of illiteracy among the participants, all questionnaires
were administered orally in a quiet private place by three trained
local hospital staff members. In addition all patients were asked
about the presence of pain (Yes/No) and itch (Yes/No), marital
status, level of education and employment. Also, for all former
patients the scar size was determined by tracing it on a
transparent sheet, scanning it, and measuring the surface with
ImageJ software.
Ethics
The study protocol was approved by the Committee on Human
Research, Publication, and Ethics of the Kwame Nkrumah
University of Science and Technology and the Komfo Anokye
Teaching Hospital, Kumasi (reference number CHRPE/AP/133/
12). Written and verbal informed consent or assent was obtained
from all participants aged $12 years, and consent from parents, or
legal representatives of participants aged #18 years.
Results
Patient population
127 individuals (84%) of the 151 former participants of the
BURULICO trial were located for follow up, and none declined
to participate. The median duration between drug treatment and
enrolment in the current study was 5 years. Although the trial
had taken place in the Ashanti region of Ghana, many former
patients had moved away from the study site, and patients were
retrieved in 9 of 10 Ghanaian regions, including the three
Northern regions more than 700 kilometers and approximately
10 hours by road from the original study site. 68% of the
retrieved former patients were female, and the median age at
follow-up was 18 years. 71 former patients were age-eligible, and
completed the DLQI, but due to an error the WHOQOL-BREF
was not administered to 4 former patients, so data on this
questionnaire were only available for 67 former patients. The
remaining 56 former patients were administered the CDLQI
only. There was no missing data on the DLQI and CDLQI, and
a maximum of 2 missing answers per QoL domain on the
WHOQOL-BREF, meaning that domain scores could be
calculated for every subject. Item 21 of the WHOQOL-BREF,
‘‘how satisfied are you with your sex life?’’, caused considerable
confusion among many former patients who were not married.
Even after repeated explanation that one could still have an
opinion about one’s sex life if you are not married (i.e. be
dissatisfied with it), it was poorly understood and hence left open
on 20 of the 67 questionnaires. Due to a printing error, the
BUFLS was not administered to one former patient, but
meaningful scores (i.e. less than 6 items not applicable) could
be computed for all other patients.
Of the 24 former patients not retrieved, 4 were already lost to
follow-up during the BURULICO trial, 3 had moved abroad, 2
had deceased, and the fate of the remaining 15 was unknown. The
former patients that were lost to follow-up did not differ
significantly from those that were retrieved in terms of age,
gender or treatment arm.
Quality of Life scores and patient characteristics
Scores, range, and reliability for the DLQI, CDLQI, and
WHOQOL-BREF subscales are shown in Table 1. The frequency
distributions of the QoL scales are shown in Figure 1. Upon
inspection, it appears that the psychological and environmental
subscales of the WHOQOL-BREF were normally distributed.
The distribution of the DLQI and CDLQI is skewed to the left.
The banding scores for the DLQI and CDLQI are shown in
Table 2.
Table 1. Scale descriptives for the DLQI, CDLQI and WHOQOL-BREF subscales.
Scale Mean (SD) Median (IQR) Range Cronbach’s a
DLQI 2.3 (3.4) 0 (0–4) 0–11 .78
CDLQI 2.6 (3.2) 1 (0–4.5) 0–11 .57
WHOQOL-BREF Physical 75.9 (12.0) 80 (69–86) 37–94 .63
WHOQOL-BREF Psychological 70.9 (12.1) 70 (60–80) 40–97 .62
WHOQOL-BREF Social 67.9 (18.0) 68 (53–80) 20–100 .55
WHOQOL-BREF Environmental 65.1 (11.6) 68 (58–73) 35–88 .66
N= 71 for the DLQI, N = 67 for the WHOQOL-BREF, and N= 56 for the CDLQI. SD = standard deviation, IQR = interquartile range. DLQI =Dermatology Life Quality Index,
CDLQI = Childrens Dermatology Life Quality Index, WHOQOL-BREF = abbreviated World Health Organisation Quality of Life instrument.
doi:10.1371/journal.pntd.0002964.t001
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Former patients had a median (IQR) scar size of 4.6 (1.4–13.5)
cm2, and a median (IQR) BUFLS score of 2.6% (0%–13.3%). Only
4 (3%) former patients were unemployed, all others were either
studying or working. Only 52% of former patients were married, but
those not married were significantly younger (t=22.31; p=0.024).
The scar was itchy in 26% and painful in 9% of former patients.
Associations between Quality of Life instruments and
patient characteristics
Spearman’s Rho correlations between the DLQI, CDLQI and
WHOQOL-BREF subscales and other continuous variables are
shown in Table 3. Age was not significantly related to any of the
QoL scales. Scar size correlated significantly with the DLQI
Figure 1. Frequency distributions of the DLQI, CDLQI, and WHOQOL-BREF scores. Theoretical range (C)DLQI = 0–30, WHOQOL= 20–100.
DLQI =Dermatology Life Quality Index, CDLQI =Childrens Dermatology Life Quality Index.
doi:10.1371/journal.pntd.0002964.g001
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(r=0.32; p,0.01). The BUFLS correlated significantly with the
environmental subscale of the WHOQOL-BREF (r=20.24; p,
0.05).
Relationships between the QoL instruments and discrete
variables were tested through either student T-tests or Mann-
Whitney U tests depending on whether the scales were normally
distributed. The QoL of women did not differ from men on any of
the scales or subscales. Farmers, scored significantly higher on the
social domain of QoL compared to other professions (U=435;
p=0.050). Those who were married also scored significantly
higher on the social domain than those who were single (U=375;
p=0.019). Those who were ethnically Akan scored significantly
higher on the DLQI (U=332; p=0.026), indicating lower QoL,
and significantly lower on the physical domain of QoL (U=292;
p=0.003), again indicating lower QoL than those from the
northern tribes. None of the QoL scores differed between those
that did or did not report painful or itchy scars.
The DLQI correlated significantly with the physical (r=20.54;
p,0.001) and psychological (r=20.34; p,0.001) subscales of the
WHOQOL-BREF, but did not correlate at all with the social
(r=0.00; p=0.99) and environmental (r=20.01; p=0.98)
subscales.
Quality of life of former BU patients compared to healthy
controls
Scores on the WHOQOL-BREF domains of patients and
healthy controls are shown in Figure 2. Former BU patients scored
significantly higher than controls on the physical and environ-
mental domains of the WHOQOL-BREF by Mann-Whitney U
tests. The effect sizes for the four domains were as follows: physical
0.29, environmental 0.41, psychological 0.10, and social 0.14.
Discussion
This is the first study to address QoL in former BU patients.
The former BU patients with small lesions that we studied
appeared to have a good QoL. When measured with the DLQI, a
disease specific questionnaire, 85% of patients indicated no or a
small effect of the disease on their current life. The median score
found was 0 compared to 13 in active and 3 in healed
podoconiosis patients in Ethiopia [16], and median scores between
2 and 12 in patients with various active skin diseases in South
Africa [21]. In the current study, scores on a measure of general
QoL were high, especially in the physical domain of QoL, but –
likely owing to the poor rural setting – lower on the environmental
domain, which relates to issues such as access to healthcare and
transportation, and financial resources. In addition, former
patients indicated an equal or better QoL compared to healthy
controls in all four domains measured.
As their scars and functional limitations were limited, it could be
expected that former patients would not differ much from controls
in QoL. However, it is surprising that they would report a higher
physical and environmental QoL, with small to medium effect
sizes. As controls were matched to former patients on age, gender,
village and occupation, it is difficult to explain these findings on
the basis of social or economic factors. Perhaps having been
confronted with BU and the prospect of scarring and disability,
made patients adjust their internal standards of what constitutes
good physical functioning. This, in turn, would cause them to
appreciate the preserved physical functioning they have today, a
phenomenon known as response shift [24]. One possible
explanation for indicating a better environmental QoL could be
their positive experience with the healthcare system for the
treatment of their BU, which is free of charge and relatively well-
organized in the study regions. However, it is also possible that the
interviewers were viewed by former patients as representatives of
the hospitals where they were treated, causing them to answer in a
more socially desirable way than controls. Another possible
explanation is that we followed-up a group who presented early,
in contrast with most BU patients, and that this was a consequence
of this group having more access to healthcare and other
resources, i.e. through being more educated or living less isolated,
Table 3. Spearman’s Rho correlations between QoL scales and other continuous variables.
DLQI CDLQI WHOQOL-BREF Phys WHOQOL-BREF Psy WHOQOL-BREF Soc WHOQOL-BREF Env
BUFLS .15 .11 2.14 2.10 2.02 2.24*
Age 2.01 2.01 2.16 2.20 2.06 2.08
Scar size .32** .12 2.06 2.03 .09 .14
* =p,0.05,
** = p,0.01.
DLQI =Dermatology Life Quality Index, CDLQI = Childrens Dermatology Life Quality Index, WHOQOL-BREF = abbreviated World Health Organisation Quality of Life
instrument, BUFLS = Buruli ulcer Functional Limitation Score.
doi:10.1371/journal.pntd.0002964.t003
Table 2. Banding scores of the DLQI and CDLQI.
Effect of scar or contracture on patients’ life DLQI (N=67) CDLQI (N=56)
No effect 63% 54%
Small effect 22% 32%
Moderate effect 10% 14%
Very large effect 5% 0%
Extremely large effect 0% 0%
DLQI =Dermatology Life Quality Index, CDLQI = Childrens Dermatology Life Quality Index.
doi:10.1371/journal.pntd.0002964.t002
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and hence a better baseline QoL than the average community
member.
The good QoL of former patients with small lesions found in
this study corresponded with the more physical measures of BU
sequelae. Patients had a relatively small median scar size. In
addition their level of functional limitations as measured by the
BUFLS was low, with a median score of 2.6%, compared to earlier
scores of 5.3% in a large cohort of BU patients with varying lesion
sizes that was treated outside of any study context [2], and 16% in
patients who had only received surgical or traditional treatment
[25].
The DLQI had a Cronbach’s alpha of 0.78 indicating satisfactory
internal consistency [26]. In addition, it was significantly related to
scar size, which can be seen as a proxy measure of disease severity,
and to both the psychological and physical QoL domains of the
WHOQOL-BREF in the expected directions. Similar to two
previous studies with the DLQI in Sub-Saharan Africa, we did not
find DLQI scores to be related to gender [16,21]. Together, these
findings suggest that the DLQI is a valid instrument for measuring
disease-specific QoL in BU patients aged 16 and above, although
further research in larger samples, including larger lesions is needed.
In children, the CDLQI had a low Cronbach’s alpha, and was not
related to any of the background variables, which makes it difficult
to ascertain its validity. The Cronbach’s alphas for the WHOQOL-
BREF subscales were all below 0.7, indicating questionable internal
consistency. The social domain of QoL was related to being married
and working as a farmer, and the physical and psychological
domains were related to disease specific QoL in the expected
directions. Former patients indicated a higher QoL on all 4 domains
of the WHOQOL-BREF than controls, which is rather unexpected.
In addition, item 21, satisfaction with ones sex life, was poorly
understood by those who were not married, and was left open by a
considerable proportion/number of former patients. Overall, these
data do not clearly establish the validity of the WHOQOL-BREF
for measuring general QoL in former BU patients.
The present study suffered from several limitations. First the
sample size was relatively small, with only 67 adults completing
both adult QoL instruments. As the cohort under study was
predetermined by the BURULICO trial, we were not able to
increase the sample size. This could have left the study
underpowered to pick up associations between the questionnaires
and background variables such as gender. However, several
significant associations were indeed found. In addition, we were
not able to recruit healthy controls for the DLQI and CDLQI as
these are disease specific questionnaires, and thus had to rely on
the earlier proposed norm scores, but the very low scores on both
instruments are likely to reflect good QoL. Finally, we did not
study QoL in former BU patients that were treated under normal
service conditions. These patients would have likely had larger
lesions and might have reported a lower QoL, and data on these
patients could have helped to establish the validity of the
questionnaires, although in our sample the DLQI already
correlated significantly with scar size.
In this study, we show that in BU patients who reported early
with small lesions and received either 8 weeks of streptomycin and
rifampicin or 4 weeks of streptomycin and rifampicin followed by
4 weeks of clarithromycin and rifampicin, scars were small,
functional limitations were uncommon and long term QoL was
preserved. These findings contrast the debilitating sequelae often
reported in BU, highlighting the importance of active case finding
and antimicrobial treatment of BU lesions. The Twii version of the
DLQI appeared to be a valid instrument to measure disease
specific QoL in BU patients aged 16 or older, and was quick and
easy to administer under field conditions. For children, the Twii
version of the CDLQI appeared to be a less valid instrument in
this population, though alternatives are lacking. The validity of the
WHOQOL-BREF for measuring general QoL in former BU
patients is questionable. Future studies on QoL in BU should
attempt to include patients with active BU, and should include
patients with larger lesions. In addition they should include
alternative questionnaires for measuring general QoL in BU, such
as the SF-36, or limit themselves to disease-specific QoL using the
DLQI.
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